Saturday 10 October 2026
Export all ABBV data to Excel Powerpack
AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
276.47
4.05
+1.49%
Follow ABBV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
71.08 | 107.14 | 96.82 | 175.41 |
+8 more quarters Free account |
P/S ratio |
6.91 | 6.13 | 6.61 | 6.87 | |
P/FCF ratio |
24.45 | 19.27 | 22.69 | 20.81 | |
P/Operating CF |
129.56 | 100.54 | 77.46 | 58.31 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.91 | 7.14 | 7.63 | 7.92 | |
EV/EBITDA |
19.91 | 18.52 | 19.39 | 20.90 | |
EV/Operating CF |
26.11 | 21.13 | 24.51 | 22.66 | |
EV/FCF |
27.97 | 22.44 | 26.18 | 24.01 | |
Quick Ratio |
0.49 | 0.52 | 0.41 | 0.47 | |
Current Ratio |
0.81 | 0.80 | 0.67 | 0.72 | |
Net Debt/EBITDA |
7.73 | 10.71 | 9.53 | 13.10 | |
Debt/Assets |
52.42% | 53.39% | 50.39% | 51.34% | |
Debt/Equity |
(12.03) | (11.02) | (20.91) | (26.45) | |
Asset Turnover |
0.47 | 0.46 | 0.45 | 0.43 | |
Operating CF/Net income |
0.95 | 5.59 | 2.92 | 37.76 | |
Capex/Depreciation |
(0.17) | (0.14) | (0.17) | (0.13) | |
Interest Coverage |
9.47 | 6.19 | 6.94 | 2.85 | |
Research and Development Expense of Revenue |
13.80% | 16.48% | 15.52% | 14.70% | |
Selling, General and Administrative Expense of Revenue |
21.38% | 23.85% | 23.44% | 22.62% | |
Intangible Assets out of Total Assets |
0.63 | 0.63 | 0.66 | 0.67 | |
Share Based Compensation of Revenue |
0.98% | 2.96% | 0.94% | 1.32% | |
Graham Net Nets |
(0.24) | (0.28) | (0.27) | (0.26) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.41% | 0.93% | 1.03% | 0.57% | |
Free Cash Flow Yield |
4.09% | 5.19% | 4.41% | 4.81% | |
Revenue per Share |
9.60 | 8.48 | 9.39 | 8.92 | |
Operating CF per Share |
1.94 | 2.16 | 2.95 | 3.97 | |
Capex per Share |
(0.18) | (0.15) | (0.19) | (0.22) | |
Free Cash Flow per Share |
1.76 | 2.01 | 2.76 | 3.76 | |
Cash per Share |
3.71 | 5.31 | 2.96 | 3.21 | |
Shareholders Equity per Share |
(3.33) | (3.74) | (1.82) | (1.47) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.33) | (3.74) | (1.82) | (1.47) | |
Free Cash Flow |
3,114.00 | 3,564.00 | 4,889.00 | 6,643.00 | |
Working Capital |
(7,973.00) | (8,571.00) | (14,227.00) | (10,852.00) | |
Capital Expenditures |
(322.00) | (265.00) | (329.00) | (381.00) | |
Net Current Asset Value |
(107,334.00) | (109,546.00) | (108,126.00) | (107,958.00) | |
EV/EBIT |
30.20 | 29.25 | 30.94 | 52.28 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
26.39 | 25.11 | 26.81 | 45.30 | |
| Other line items | |||||
Average Receivables |
13,230.50 | 12,478.00 | 11,754.00 | 12,120.50 | |
Average Payables |
32,773.00 | 32,407.50 | 33,339.50 | 32,055.50 | |
Average Inventory |
5,043.50 | 4,787.50 | 4,566.00 | 4,694.00 | |
Average Assets |
136,148.50 | 136,314.00 | 134,560.50 | 138,660.00 | |
Average Common Equity |
(3,013.00) | (2,575.00) | 68.00 | 1,736.00 |
Columns are period end dates